Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta

BACKGROUND/OBJECTIVE: Osteogenesis imperfecta (OI) is a genetic disorder that affects type 1 collagen synthesis causing increased bone fragility, low bone mass, and skeletal deformity. Bisphosphonates are recommended for treatment of OI patients; however, the efficacy of sclerostin inhibitors such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dattagupta, Antara, Petak, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690408/
https://www.ncbi.nlm.nih.gov/pubmed/38045794
http://dx.doi.org/10.1016/j.aace.2023.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690408/
https://www.ncbi.nlm.nih.gov/pubmed/38045794
http://dx.doi.org/10.1016/j.aace.2023.10.002

Ejemplares similares